Shares of Bruker Corporation (NASDAQ: BRKR), a global manufacturer of scientific instruments that address the needs of an array of customers in life science, pharmaceutical, biotechnology, clinical and molecular diagnostics research, as well as in materials and chemical analysis in various industries and government applications, are seeing a huge rally in trading today.
At last check, BRKR shares were trading 11.20% higher at $14 on volume of 140,896. The stock hit an intra-day high of $14.25 in trading today.
BRKR shares are soaring after the company reported its financial results for the quarter ended September 30, 2012. For the third quarter of 2012, BRKR reported revenue of $447.8 million, representing an increase of 7% over the same period in the previous year. GAAP net income for the quarter was $39.7 million, or $0.24 per share, compared to $19.8 million, or $0.12 per share reported for the same period in the previous year. Adjusted net income for the quarter was $47.1 million, or $0.28 per share, compared to $34.4 million, or $0.21 per share reported for the same period in the previous year.
Shares of Pharmacyclics Inc. (NASDAQ: PCYC), a clinical-stage biopharmaceutical company engaged in the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases, are down sharply in early trading today.
At last check, PCYC shares were trading 15.10% lower at $48.71 on above average volume of 1.26 million. The stock fell to an intra-day low of $46.56 in early trading today.
PCYC shares are sinking in early trading today after the company reported financial results and recent developments for its first quarter ended September 30, 2012. For the quarter, the company reported net income of $75.6 million, or $1.02 per diluted share. The company’s non-GAAP net income for the quarter was $78.8 million, or $1.07 per diluted share reported for the same period in the previous year. The company’s revenue for the quarter was $102.7 million, compared to $37,000 reported for the same period in the previous year.
The company also said that nine oral presentations and seven poster presentations for its BTK Inhibitor Ibrutinib (PCI-32765) and one oral presentation and one poster presentation for its HDAC Inhibitor Abexinostat (PCI-24781) have been accepted at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a Novato, California-based biotechnology company engaged in the development and commercialization of pharmaceuticals for serious diseases and medical conditions, are seeing a huge rally in trading today.
At last check, BMRN shares were trading 29.51% higher at $48.45 on above average volume of 4.58 million. The stock hit a 52-week high of $48.61 in trading today.
BMRN shares are soaring in trading today after the announced that the Phase 3 study of GALNS for the treatment of MPS IVA met the primary endpoint of change in six-minute walk distance compared with placebo at 24 weeks. Hank Fuchs, M.D., Chief Medical Officer at BioMarin, said that the positive results from the pivotal study will help support GALNS as the first therapy available to help the approximate 3,000 people worldwide suffering from MPS-IVA—a rare, degenerative, life-threatening genetic condition with no available therapy.
Recent Comments